Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > $3.50

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Nov 05, 2021 2:51pm

140 Views

Post# 34093514

RE:RE:RE:RE:RE:$3.50

That has to be considered a possibility. Obviously, that would not be a good sign for cancer if true. Leah's leaving might be understandable if that is what is going on. Last I heard, however, is they had no intention of using it now and I hope that proves true. Given the superlatives used to describe the cancer recently, it would be surprising if they were using the ATM prior to the release of the data.